News Column

Response Biomedical Corp. Announces Voting Results

Jun 19 2013 12:00AM

Marketwire

LogoTracker

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/19/13 -- Response Biomedical Corp. (TSX: RBM) (OTCBB: RPBIF) (the "Company"), in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2013 Annual General and Special Meeting of Shareholders held on June 18, 2013.

A total of 4,675,917 common shares were voted in connection with the meeting, representing approximately 71% of the issued and outstanding common shares of the Company. Shareholders voted as follows:

1. Appointment of Auditor

By resolution passed by show of hands, PricewaterhouseCoopers LLP, Chartered Accountants, was appointed auditor of the Company for the ensuing year.

2. Election of Directors

By resolution passed by show of hands, the number of Directors of the Company was set at 8. By resolution passed by ballot vote, the following eight nominees proposed by Management were elected as Directors of the Company to hold office until the next Annual Meeting of Shareholders or until their successors are elected or appointed:

% Votes VotesNominee Votes For For Withheld % Votes Withheld----------------------------------------------------------------------------Dr. Anthony Holler, M.D. 4,429,546 99.95% 2,142 0.05%----------------------------------------------------------------------------Dr. Joseph D. Keegan, Ph.D. 4,429,546 99.95% 2,142 0.05%----------------------------------------------------------------------------Jeffrey L. Purvin 4,428,620 99.93% 3,068 0.07%----------------------------------------------------------------------------Clinton H. Severson 4,429,539 99.95% 2,149 0.05%----------------------------------------------------------------------------Lewis J. Shuster 4,429,539 99.95% 2,149 0.05%----------------------------------------------------------------------------Dr. Peter A. Thompson, M.D. 4,428,875 99.94% 2,813 0.06%----------------------------------------------------------------------------Dr. David G. Wang, M.D. 4,428,558 99.93% 3,130 0.07%----------------------------------------------------------------------------Dr. Jonathan J. Wang, Ph.D. 4,428,310 99.92% 3,378 0.08%----------------------------------------------------------------------------



3. Amendment and Restatement of 2008 Stock Option Plan

By resolution passed by show of hands, the amendment and restatement of the Company's 2008 Stock Option Plan as outlined in the Company's information circular, and the approval of all unallocated options to acquire common shares under the Amended and Restated 2008 Stock Option Plan until June 18, 2016, were approved.

4. Amendment to Amended and Restated 2008 Stock Option Plan

By resolution passed by ballot vote, an amendment to the Amended and Restated 2008 Stock Option Plan to remove insider participation limits was approved by disinterested shareholders. The results of the ballot were as follows:

Votes % Votes Votes % Votes Votes For % Votes For Against Against Withheld Withheld---------------------------------------------------------------------------- 285,873 94.63% 16,226 5.37% 0 0.00%----------------------------------------------------------------------------



4,129,589 shares held by insiders of the Company were not counted for purposes of this resolution.

5. Approval of Restricted Share Unit Plan

By resolution passed by show of hands, the Company's Restricted Share Unit Plan as outlined in the Company's management information circular, and the approval of all unallocated restricted share units under the Restricted Share Unit Plan until June 18, 2016, were approved.

6. Approval of Non-Employee Director Deferred Share Unit Plan

By resolution passed by show of hands, the Company's Non-Employee Director Deferred Share Unit Plan as outlined in the Company's management information circular, and the approval of all unallocated deferred share units under the Non-Employee Director Deferred Share Unit Plan until June 18, 2016, were approved.

7. Amendment to Restricted Share Unit Plan

By resolution passed by ballot vote, an amendment to the Restricted Share Unit Plan to remove insider participation limits was approved by disinterested shareholders. The results of the ballot were as follows:

Votes % Votes Votes % Votes Votes For % Votes For Against Against Withheld Withheld---------------------------------------------------------------------------- 292,648 96.87% 9,444 3.13% 7 0.00%----------------------------------------------------------------------------



4,129,589 shares held by insiders of the Company were not counted for purposes of this resolution.

8. Amendment to Non-Employee Director Deferred Share Unit Plan

By resolution passed by ballot vote, an amendment to the Non-Employee Director Deferred Share Unit Plan to remove insider participation limits was approved by disinterested shareholders. The results of the ballot were as follows:

Votes % Votes Votes % Votes Votes For % Votes For Against Against Withheld Withheld---------------------------------------------------------------------------- 293,727 97.23% 8,370 2.77% 2 0.00%----------------------------------------------------------------------------



4,129,589 shares held by insiders of the Company were not counted for purposes of this resolution.

9. Approval of Option Grants

By resolution passed by ballot vote, the issuance of certain options to acquire common shares issued to the Board of Directors and certain members of Management as outlined in the Company's management information circular was approved by disinterested shareholders. The results of the ballot were as follows:

Votes % Votes Votes % Votes Votes For % Votes For Against Against Withheld Withheld---------------------------------------------------------------------------- 282,582 93.54% 19,515 6.46% 2 0.00%----------------------------------------------------------------------------



4,129,589 shares held by insiders of the Company were not counted for purposes of this resolution.

10. Non-Binding Advisory Vote on Executive Compensation

By resolution passed by ballot vote, an advisory resolution was passed to approve the Company's executive compensation as outlined in the Company's management information circular. The results of the ballot were as follows:

Votes % Votes Votes % Votes Votes For % Votes For Against Against Withheld Withheld---------------------------------------------------------------------------- 4,423,229 99.81% 8,459 0.19% 0 0.00%----------------------------------------------------------------------------



11. Non-Binding Advisory Vote on Frequency of Future Advisory Votes on Compensation

By resolution passed by ballot vote, an advisory resolution on the frequency of future advisory votes on compensation, determined, on a non-binding advisory basis, that the Company should hold future advisory votes on compensation every 3 years. The results of the ballot were as follows:

% Votes For Votes For 2 % Votes for Votes For 3 % Votes ForVotes For 1 Year 1 Year Years 2 Years Years 3 Years---------------------------------------------------------------------------- 79,353 1.79% 40.380 0.91% 4,311,955 97.30%----------------------------------------------------------------------------



About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable laboratory quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, Flu A + B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. More information on the proprietary RAMP® Platform can be found at www.responsebio.com.

The Company has achieved CE Marking and 510(k) clearance for Response Infectious Disease and Response Cardiovascular tests on the RAMP® Platform and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.



Contacts:
Response Biomedical Corp.
W.J.(Bill) Adams
604-456-6010
Chief Financial Officer
ir@responsebio.com
www.responsebio.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters